Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2005-11-01
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S224000, C546S213000, C514S326000
Reexamination Certificate
active
06960602
ABSTRACT:
The invention provides a compound of formula (I): wherein R1, R2, R3, R3a, R4, R4a, R5, and R6are as defined; or a pharmaceutically acceptable salt thereof or a solvate thereof; compositions containing these compounds, processes for preparing them and their use as modulators of chemokine activity (especially CCR5 activity)
REFERENCES:
patent: 3203992 (1965-08-01), Kunz et al.
patent: 3577432 (1971-05-01), Helsley et al.
patent: 3755584 (1973-08-01), Plotnikoff et al.
patent: 3818017 (1974-06-01), Janssen et al.
patent: 3894030 (1975-07-01), Janssen et al.
patent: 4029801 (1977-06-01), Cavalla et al.
patent: 4105666 (1978-08-01), Ward
patent: 4105771 (1978-08-01), Archibald et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4246267 (1981-01-01), Vincent et al.
patent: 4264613 (1981-04-01), Regnier et al.
patent: 4338323 (1982-07-01), Regnier et al.
patent: 5576321 (1996-11-01), Krushinski, Jr. et al.
patent: 5614523 (1997-03-01), Audia et al.
patent: 5614533 (1997-03-01), Anderson et al.
patent: 5627196 (1997-05-01), Audia et al.
patent: 5688960 (1997-11-01), Shankar
patent: 5696267 (1997-12-01), Reichard et al.
patent: 5741789 (1998-04-01), Hibschman et al.
patent: 5789402 (1998-08-01), Audia et al.
patent: 5840725 (1998-11-01), Reichard et al.
patent: 37 23 568 (1989-01-01), None
patent: 197 03 131 (1998-07-01), None
patent: 197 55 268 (1999-06-01), None
patent: 0 095 454 (1983-11-01), None
patent: 0 128 007 (1984-12-01), None
patent: 0 354 568 (1990-02-01), None
patent: 0 407 217 (1991-01-01), None
patent: 0 445 862 (1991-09-01), None
patent: 0 457 686 (1991-11-01), None
patent: 0 496 691 (1992-07-01), None
patent: 0 587 311 (1994-03-01), None
patent: 0 625 507 (1994-11-01), None
patent: 0 643 057 (1995-03-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 903 349 (1999-05-01), None
patent: 1 013 276 (2000-06-01), None
patent: 2 190 430 (1974-02-01), None
patent: 1 368 012 (1974-09-01), None
patent: 1 404 868 (1975-09-01), None
patent: 1 425 354 (1976-02-01), None
patent: 1 532 671 (1978-11-01), None
patent: 1 538 542 (1979-01-01), None
patent: 1 544 191 (1979-04-01), None
patent: 63-264525 (1988-11-01), None
patent: 10259176 (1998-09-01), None
patent: WO 92/15579 (1992-09-01), None
patent: WO 93/13083 (1993-07-01), None
patent: WO 93/25528 (1993-12-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 95/11880 (1995-05-01), None
patent: WO 96/26205 (1996-08-01), None
patent: WO 96/34857 (1996-11-01), None
patent: WO 96/39386 (1996-12-01), None
patent: WO 97/10207 (1997-03-01), None
patent: WO 97/19060 (1997-05-01), None
patent: WO 97/23458 (1997-07-01), None
patent: WO 97/42956 (1997-11-01), None
patent: WO 97/47299 (1997-12-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/08826 (1998-03-01), None
patent: WO 98/31364 (1998-07-01), None
patent: WO 98/31366 (1998-07-01), None
patent: WO 98/32442 (1998-07-01), None
patent: WO 98/51311 (1998-11-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/27928 (1999-06-01), None
patent: WO 99/27929 (1999-06-01), None
patent: WO 99/28314 (1999-06-01), None
patent: WO 99/31092 (1999-06-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 99/37619 (1999-07-01), None
patent: WO 99/38514 (1999-08-01), None
patent: WO 99/64394 (1999-12-01), None
patent: WO 99/65895 (1999-12-01), None
patent: WO 00/08013 (2000-02-01), None
patent: WO 00/21948 (2000-04-01), None
patent: WO 00/21952 (2000-04-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/39108 (2000-07-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/58305 (2000-10-01), None
patent: WO 00/61559 (2000-10-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 00/76513 (2000-12-01), None
patent: WO 00/76973 (2000-12-01), None
patent: WO 01/14333 (2001-03-01), None
patent: WO 01/43744 (2001-06-01), None
patent: WO 01/44227 (2001-06-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 01/92227 (2001-12-01), None
patent: WO 02/066460 (2002-08-01), None
patent: WO 02/070479 (2002-09-01), None
patent: WO 02/076948 (2002-10-01), None
patent: WO 02/079256 (2002-10-01), None
patent: WO 03/042177 (2003-05-01), None
patent: WO 03/042178 (2003-05-01), None
patent: WO 03/042205 (2003-05-01), None
Mensonides-Harsema et al., “Synthesis and in Vitro and in Vivo Functional Studies of Ortho-Substituted Phenylpiperazine and N-Substituted 4-N-(o-Methoxyphenyl)aminopiperidine Analogues of WAY100635,” J. Med. Chem., vol. 43, pp. 432-439 (2000).
Archibald et al., “Antihypertensive Ureidopiperidines”,J. Med. Chem. 23:857-861(1980).
Archibald et al., “Antiinflammatory 4-acylaminopiperidines”, CAPLUS 77:34355 (1972).
Caplus accession No. 1978:22640, document No. 88:22640, Yoshitomi Pharmaceutical Industries Ltd.: “Urea and thiourea derivatives” & JP, A2, 52085174, 19770715.
Caplus, accession No. 1990:558675, document No. 113:158675, Yoshitomi Pharmaceutical Industries, Ltd.: “Dihydroxycinnamic acid amide derivatives and their pharmaceutical compositions for enhancement of nerve growth factor (NGF) production” & JP, A2, 02104568, 19900417.
Cattanach et al., “Studies in the Indole Series. Part IV. Tetrahydro-1H-pyrido[4, 3-b]-indoles as Serotonin Antagonists”,J. Chem. Soc.(C) 10:1235-1243 (1968).
Cohen et al., “Cytokine function: A study in biologic diversity”, Caplus 125:31527 (1996).
Derwent Abstract 2000-587420/55, (2003), corresponding to Foreign Patent Document WO 00/53600, published Sep. 14, 2000 (Reference AYYY above).
Derwent Abstract 54050W/33 corresponding to Belgium Application BE 826994.
Derwent Abstract 93-339628/29 corresponding to PCT Application WO 00/23437 A1.
Derwent Abstract 96-136185/14 corresponding to Japanese Patent Application JP 08026999.
Derwent Abstract 96-136186/14 corresponding to Japanese Patent Application JP 08027000-A.
Derwent Abstract 96-136187/14 corresponding to Japanese Patent Application JP 08027001-A.
Derwent Abstract 97-212513/19, (2003), corresponding to Foreign Patent Document WO 97/10207 A1, published Mar. 20, 1997 (Reference AWW above).
Derwent Abstract 98-351249/49, (2003), corresponding to Foreign Patent Document JP 63-264525, published Nov. 1, 1988 (Reference AOO above).
Derwent Abstract 99-040684/04 corresponding to Japanese Patent Application JP 10298180-A/2.
Emonds-Alt et al., “Pharmacological Profile and Chemical Synthesis of SR 48968, a Non-Peptide Antagonist of the Neurokinin A (NK2) Receptor”,Bioorganic & Medicinal Chemistry Letters3(5):925-930 (1993).
Friebe et al., “Piperidinopropyl derivatives and pharmaceutical compositions containing them”, CAPLUS 94:103172 (1981).
Gerard, “Chemokine Receptors and Ligand Specificity: Understanding the Enigma”,Chemokines and Cancervol. 13, No. 72 (C-570):21-31, Feb. 17, 1999.
Granata et al., “Secretory phospholipases a(2) as multivalent mediators of inflammatory and allergic disorders”, PubMed Abstract 12876405, also citedas Int Arch Allergy Immunol. 131(3):153-163 (2003).
Hesselgesser et al., “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,J. Biol. Chem. 273(25):15687-15692 (1998).
Howard et al., “Chemokines: progress toward identifying molecular targets for therapeutic agents”,Trends in Biotechnology14:46-51 (1996).
Janda, “A Soluble Polmer Approach to the “Fishing Out” Principle: Synthesis and Purification of β-Amino Alcohols”,J. Org. Chem. 63:889-894 (1998).
Komai et al., “Structure-Activity Relationships of HIV-1 PR Inhibitors Containing AHPBA-II. Modification of Pryrrolidine Ring at P1'Proline”,Bioorganic & Medicinal Chemistry4(8):1365-1377 (1996).
Lawrence et al., “Automated Synthesis and Purification of Amides: Exploitation of Automated Solid Phase Extraction in Orga
Burrows Jeremy
Cumming John
AstraZeneca AB
Aulakh Charanjit S.
LandOfFree
Piperidine derivatives as modulators of chemokine receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives as modulators of chemokine receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives as modulators of chemokine receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463105